Non-invasive determination of myocardial lipid content in fabry disease by 1H-MR spectroscopy

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 184, Issue 11, 2012, Pages 1020-1025

  Petritsch, B ^a   Kostler H ^a   MacHann, W ^a   Horn, M ^a   Weng, A M ^a   Goltz, J P ^a   Hahn, D ^a   Niemann, M ^a   Weidemann, F ^a   Wanner, C ^a   Beer, M ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

cardiac; genetic defects; molecular imaging; MR imaging; MR spectroscopy

Indexed keywords

GADOBENATE DIMEGLUMINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FABRY DISEASE; FEMALE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HEART MUSCLE FIBROSIS; HUMAN; IMAGE ENHANCEMENT; IN VIVO STUDY; LIPID ANALYSIS; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TISSUE LEVEL;

ADOLESCENT; ADULT; AGED; FABRY DISEASE; FEMALE; GLYCOSPHINGOLIPIDS; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; TRIGLYCERIDES; TRIHEXOSYLCERAMIDES; YOUNG ADULT;

EID: 84867899163     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0032-1313059     Document Type: Article

References (31)

1. Desnick R. J., Banikazemi M. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy. Nephrol Ther: 2006; 2 S172 S185
2. Breunig F., Weidemann F., Beer M. et al. Fabry disease: diagnosis and treatment. Kidney Int Suppl: 2003; 63 S181 S185
3. Beer M., Weidemann F., Breunig F. et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabrys cardiomyopathy. Am J Cardiol: 2006; 97 1515 1518
4. Moon J. C., Sachdev B., Elkington A. G. et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J: 2003; 24 2151 2155
5. Silva C., Moon J. C., Elkington A. G. et al. Myocardial late gadolinium enhancement in specific cardiomyopathies by cardiovascular magnetic resonance: a preliminary experience. J Cardiovasc Med: 2007; 8 1076 1079
6. Lucke T., Hoppner W., Schmidt E. et al. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Mol Genet Metab: 2004; 82 93 97
7. Takenaka T., Teraguchi H., Yoshida A. et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol: 2008; 51 50 59
8. Laser J. A., Fowles R. E., Mason J. W. Endomyocardial biopsy. Cardiovasc Clin: 1985; 15 141 163
9. Yilmaz A., Kindermann I., Kindermann M. et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation: 2010; 122 900 909
10. 1H magnetic resonance spectroscopic imaging. Magn Reson Med: 1994; 32 175 180
11. OConnor R. D., Xu J., Ewald G. A. et al. Intramyocardial triglyceride quantification by magnetic resonance spectroscopy: In vivo and ex vivo correlation in human subjects. Magn Reson Med: 2011; 65 1234 1238
12. 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology: 2007; 245 251 257
13. Schar M., Kozerke S., Boesiger P. Navigator gating and volume tracking for double-triggered cardiac proton spectroscopy at 3 Tesla. Magn Reson Med: 2004; 51 1091 1095
14. 1H-magnetic resonance spectroscopy study. Circulation: 2007; 116 1170 1175
15. Al-Fadhli A., Wahidulla S., DSouza L. Glycolipids from the red alga Chondria armata (Kutz Okamura). Glycobiology: 2006; 16 902 915
16. Simonetti O. P., Kim R. J., Fieno D. S. et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology: 2001; 218 215 223
17. Szczepaniak L. S., Dobbins R. L., Metzger G. J. et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med: 2003; 49 417 423
18. Strobel K., van den Hoff J., Pietzsch J. Localized proton magnetic resonance spectroscopy of lipids in adipose tissue at high spatial resolution in mice in vivo. J Lipid Res: 2008; 49 473 480
19. Desnick R. J., Brady R., Barranger J. et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med: 2003; 138 338 346
20. Kalliokoski R. J., Kalliokoski K. K., Sundell J. et al. Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis: 2005; 28 563 573
21. Machann W., Breunig F., Weidemann F. et al. Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A. Eur J Heart Fail: 2011; 13 278 283
22. Cikes M., Sutherland G. R., Anderson L. J. et al. The role of echocardiographic deformation imaging in hypertrophic myopathies. Nat Rev Cardiol: 2010; 7 384 396
23. Rijzewijk L. J., van der Meer R. W., Smit J. W. et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol: 2008; 52 1793 1799
24. van der Meer R. W., Rijzewijk L. J., de Jong H. W. et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation: 2009; 119 2069 2077
25. White L. J., Ferguson M. A., McCoy S. C. et al. Cardiovascular/non- insulin-dependent diabetes mellitus risk factors and intramyocellular lipid in healthy subjects: a sex comparison. Metabolism: 2006; 55 128 134
26. Schrauwen-Hinderling V. B., Hesselink M. K., Meex R. et al. Improved ejection fraction after exercise training in obesity is accompanied by reduced cardiac lipid content. J Clin Endocrinol Metab: 2010; 95 1932 1938
27. 1H MR spectroscopy. Radiology: 2005; 236 609 614
28. 1H MRS. J Magn Reson Imaging: 2008; 28 1201 1208
29. 1H MRS at 3 Tesla. Magn Reson Med: 2011; 66 619 624
30. Nakagawa Y., Hattori M., Harada K. et al. Age-related changes in intramyocellular lipid in humans by in vivo H-MR spectroscopy. Gerontology: 2007; 53 218 223
31. Reingold J. S., McGavock J. M., Kaka S. et al. Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. Am J Physiol Endocrinol Metab: 2005; 289 E935 E939